Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$21.80
-0.05-0.23%
After Hours: 8:19 AM EDT
Comments
Loading...
Vera Therapeutics Analyst Ratings and Price Targets | NASDAQ:VERA | Benzinga
Vera Therapeutics Inc has a consensus price target of $52.15 based on the ratings of 13 analysts. The high is $100 issued by Cantor Fitzgerald on May 7, 2025. The low is $6 issued by Jefferies on January 4, 2023. The 3 most-recent analyst ratings were released by Scotiabank, HC Wainwright & Co., and Wedbush on June 2, 2025, June 2, 2025, and May 7, 2025, respectively. With an average price target of $58.67 between Scotiabank, HC Wainwright & Co., and Wedbush, there's an implied 179.37% upside for Vera Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Scotiabank
HC Wainwright & Co.
Wedbush
Cantor Fitzgerald
JP Morgan
1calculated from analyst ratings
Analyst Ratings for Vera Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/02/2025 | Buy Now | 209.52% | Scotiabank | Greg Harrison47% | $55 → $65 | Maintains | Sector Outperform | Get Alert |
| 06/02/2025 | Buy Now | 304.76% | HC Wainwright & Co. | Arthur He35% | $75 → $85 | Maintains | Buy | Get Alert |
| 05/07/2025 | Buy Now | 23.81% | Wedbush | Laura Chico51% | $34 → $26 | Maintains | Neutral | Get Alert |
| 05/07/2025 | Buy Now | 376.19% | Cantor Fitzgerald | Pete Stavropoulos41% | $107 → $100 | Maintains | Overweight | Get Alert |
| 05/05/2025 | Buy Now | 257.14% | HC Wainwright & Co. | Arthur He35% | → $75 | Assumes | → Buy | Get Alert |
| 03/04/2025 | Buy Now | 238.1% | JP Morgan | Anupam Rama59% | $77 → $71 | Maintains | Overweight | Get Alert |
| 02/27/2025 | Buy Now | 190.48% | Guggenheim | Vamil Divan74% | $59 → $61 | Maintains | Buy | Get Alert |
| 02/04/2025 | Buy Now | 133.33% | Wolfe Research | Andy Chen46% | → $49 | Initiates | → Outperform | Get Alert |
| 11/21/2024 | Buy Now | 233.33% | Wells Fargo | Mohit Bansal68% | → $70 | Initiates | → Overweight | Get Alert |
| 11/08/2024 | Buy Now | 80.95% | Wedbush | Laura Chico51% | $30 → $38 | Maintains | Neutral | Get Alert |
| 11/05/2024 | Buy Now | 257.14% | JP Morgan | Anupam Rama59% | $72 → $75 | Maintains | Overweight | Get Alert |
| 10/28/2024 | Buy Now | 204.76% | Guggenheim | Vamil Divan74% | $56 → $64 | Maintains | Buy | Get Alert |
| 10/16/2024 | Buy Now | 185.71% | Scotiabank | Greg Harrison47% | → $60 | Initiates | → Sector Outperform | Get Alert |
| 10/03/2024 | Buy Now | 409.52% | Cantor Fitzgerald | Pete Stavropoulos41% | $107 → $107 | Reiterates | Overweight → Overweight | Get Alert |
| 10/01/2024 | Buy Now | 409.52% | Cantor Fitzgerald | Pete Stavropoulos41% | $107 → $107 | Reiterates | Overweight → Overweight | Get Alert |
| 09/23/2024 | Buy Now | 409.52% | Cantor Fitzgerald | Pete Stavropoulos41% | $107 → $107 | Reiterates | Overweight → Overweight | Get Alert |
| 09/16/2024 | Buy Now | 409.52% | Cantor Fitzgerald | Pete Stavropoulos41% | $107 → $107 | Reiterates | Overweight → Overweight | Get Alert |
| 09/09/2024 | Buy Now | 409.52% | Cantor Fitzgerald | Pete Stavropoulos41% | $107 → $107 | Reiterates | Overweight → Overweight | Get Alert |
| 09/06/2024 | Buy Now | 409.52% | Cantor Fitzgerald | Pete Stavropoulos41% | $107 → $107 | Reiterates | Overweight → Overweight | Get Alert |
| 09/03/2024 | Buy Now | 242.86% | JP Morgan | Anupam Rama59% | $62 → $72 | Maintains | Overweight | Get Alert |
| 08/13/2024 | Buy Now | 195.24% | JP Morgan | Anupam Rama59% | $65 → $62 | Maintains | Overweight | Get Alert |
| 05/31/2024 | Buy Now | 209.52% | JP Morgan | Anupam Rama59% | $60 → $65 | Maintains | Overweight | Get Alert |
| 05/10/2024 | Buy Now | 223.81% | Raymond James | Steven Seedhouse57% | $57 → $68 | Maintains | Strong Buy | Get Alert |
| 04/05/2024 | Buy Now | 166.67% | Guggenheim | Vamil Divan74% | $56 → $56 | Reiterates | Buy → Buy | Get Alert |
| 03/27/2024 | Buy Now | 166.67% | Guggenheim | Vamil Divan74% | $27 → $56 | Maintains | Buy | Get Alert |
| 03/21/2024 | Buy Now | 61.9% | Wedbush | Laura Chico51% | $21 → $34 | Maintains | Neutral | Get Alert |
| 01/26/2024 | Buy Now | — | Wedbush | Laura Chico51% | $16 → $21 | Maintains | Neutral | Get Alert |
| 01/26/2024 | Buy Now | 76.19% | Raymond James | Steven Seedhouse57% | $29 → $37 | Upgrade | Outperform → Strong Buy | Get Alert |
| 01/25/2024 | Buy Now | 23.81% | Oppenheimer | Justin Kim36% | → $26 | Initiates | → Outperform | Get Alert |
| 01/08/2024 | Buy Now | — | Cantor Fitzgerald | Pete Stavropoulos41% | — | Initiates | → Overweight | Get Alert |
| 12/27/2023 | Buy Now | 19.05% | HC Wainwright & Co. | Ed Arce63% | $25 → $25 | Reiterates | Buy → Buy | Get Alert |
| 12/18/2023 | Buy Now | 38.1% | Raymond James | Steven Seedhouse57% | → $29 | Initiates | → Outperform | Get Alert |
| 11/30/2023 | Buy Now | 4.76% | JP Morgan | Anupam Rama59% | $25 → $22 | Maintains | Overweight | Get Alert |
| 11/10/2023 | Buy Now | 23.81% | Jefferies | Farzin Haque57% | $18 → $26 | Upgrade | Hold → Buy | Get Alert |
| 09/26/2023 | Buy Now | 19.05% | HC Wainwright & Co. | Ed Arce63% | $10 → $25 | Maintains | Buy | Get Alert |
| 08/16/2023 | Buy Now | 28.57% | Guggenheim | Vamil Divan74% | → $27 | Initiates | → Buy | Get Alert |
| 08/11/2023 | Buy Now | -23.81% | Wedbush | Laura Chico51% | $12 → $16 | Maintains | Neutral | Get Alert |
| 06/08/2023 | Buy Now | -52.38% | HC Wainwright & Co. | Ed Arce63% | → $10 | Reiterates | Buy → Buy | Get Alert |
| 05/12/2023 | Buy Now | -52.38% | HC Wainwright & Co. | Ed Arce63% | $11 → $10 | Maintains | Buy | Get Alert |
| 05/12/2023 | Buy Now | -57.14% | Wedbush | Laura Chico51% | $6 → $9 | Maintains | Neutral | Get Alert |
| 04/12/2023 | Buy Now | 4.76% | JP Morgan | Anupam Rama59% | $38 → $22 | Maintains | Overweight | Get Alert |
| 03/29/2023 | Buy Now | -47.62% | HC Wainwright & Co. | Ed Arce63% | $15 → $11 | Maintains | Buy | Get Alert |
| 01/04/2023 | Buy Now | -71.43% | Jefferies | Maury Raycroft33% | $32 → $6 | Downgrade | Buy → Hold | Get Alert |
| 01/04/2023 | Buy Now | -61.9% | Wedbush | Laura Chico51% | → $8 | Downgrade | Outperform → Neutral | Get Alert |
| 01/04/2023 | Buy Now | -28.57% | HC Wainwright & Co. | Ed Arce63% | $36 → $15 | Maintains | Buy | Get Alert |
| 11/18/2022 | Buy Now | 80.95% | JP Morgan | Anupam Rama59% | $35 → $38 | Maintains | Overweight | Get Alert |
| 08/22/2022 | Buy Now | 71.43% | HC Wainwright & Co. | Ed Arce63% | $35 → $36 | Maintains | Buy | Get Alert |
| 07/12/2022 | Buy Now | 66.67% | JP Morgan | Anupam Rama59% | → $35 | Initiates | → Overweight | Get Alert |
FAQ
What is the target price for Vera Therapeutics (VERA) stock?
The latest price target for Vera Therapeutics (NASDAQ:VERA) was reported by Scotiabank on June 2, 2025. The analyst firm set a price target for $65.00 expecting VERA to rise to within 12 months (a possible 198.17% upside). 21 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Vera Therapeutics (VERA)?
The latest analyst rating for Vera Therapeutics (NASDAQ:VERA) was provided by Scotiabank, and Vera Therapeutics maintained their sector outperform rating.
When was the last upgrade for Vera Therapeutics (VERA)?
The last upgrade for Vera Therapeutics Inc happened on January 26, 2024 when Raymond James raised their price target to $37. Raymond James previously had an outperform for Vera Therapeutics Inc.
When was the last downgrade for Vera Therapeutics (VERA)?
The last downgrade for Vera Therapeutics Inc happened on January 4, 2023 when Jefferies changed their price target from $32 to $6 for Vera Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Vera Therapeutics (VERA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Vera Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Vera Therapeutics was filed on June 2, 2025 so you should expect the next rating to be made available sometime around June 2, 2026.
Is the Analyst Rating Vera Therapeutics (VERA) correct?
While ratings are subjective and will change, the latest Vera Therapeutics (VERA) rating was a maintained with a price target of $55.00 to $65.00. The current price Vera Therapeutics (VERA) is trading at is $21.80, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
